A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)

NCT04691141 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped The study was stopped early because the sponsor decided to change the study-drug development strategy

Conditions

Interventions

Sponsor

Shanghai Antengene Corporation Limited